Optimal dose of angiotensin‐converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection
Authors:
- 19 May 2010
- journal article
- review article
- Published by Wiley in Nephrology
- Vol. 15 (s2) , 57-60
Abstract
Angiotensin‐converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) have become the cornerstone in the treatment of chronic kidney disease (CKD), as numerous lines of evidence have shown that these agents have a blood pressure lowing independent anti‐proteinuric effect. However, despite the benefits of ACEI or ARB therapy, a substantial proportion of patients still experience renal morbidity and mortality. Considering the prognostic impact of proteinuria reduction, it is currently assumed that titration of ACEI or ARB for optimal anti‐proteinuric effect would be a logical step towards improvement of renoprotection. Recent published studies, performed with higher than recommended doses of either ACEI or particularly ARB, suggest that the approach is associated with a further decrement in urinary protein excretion and probably improved renal outcome. Although most patients achieve their maximum benefit at standard doses, there is a residual group of patients who may do so at higher doses of renin‐angiotensin system inhibitors. Because patients who would benefit from higher doses are not identifiable a priori, a titration process might be cogent in order to provide more robust anti‐proteinuric benefit to such patients.Keywords
This publication has 19 references indexed in Scilit:
- Supramaximal Dose of Candesartan in Proteinuric Renal DiseaseJournal of the American Society of Nephrology, 2009
- Supratherapeutic Doses of Angiotensin Receptor Blockers to Decrease Proteinuria in Patients with Chronic Kidney DiseaseAmerican Journal of Nephrology, 2007
- Renoprotection of Optimal Antiproteinuric Doses (ROAD) StudyJournal of the American Society of Nephrology, 2007
- Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic NephropathyJournal of the American Society of Nephrology, 2007
- Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetesJournal of Clinical Investigation, 2006
- Long-Term Renoprotective Effects of Standard Versus High Doses of Telmisartan in Hypertensive Nondiabetic NephropathiesAmerican Journal of Kidney Diseases, 2005
- Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuriaKidney International, 2005
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAALKidney International, 2004
- Glomerular permselectivity in early stages of overt diabetic nephropathyKidney International, 2000
- Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathyKidney International, 2000